Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study

What Was Tested

The paper reports a study of Octreotide, published as a clinical trial, phase ii.

The most important factor for long-term survival of thymoma patients is complete resection (R0) of the tumor.

The researchers therefore evaluated the response to and the induction of resectability of primarily or locally recurrent unresectable thymomas and thymic carcinomas by octreotide Long-Acting Release (LAR) plus prednisone therapy in patients with positive octreotide scans.

Who Took Part

According to the abstract, 17 patients were involved.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

In this open label, single-arm phase II study, 17 patients with thymomas considered unresectable or locally recurrent thymoma (n = 15) and thymic carcinoma (n = 2) at Masaoka stage III were enrolled.

How the Study Was Run

In design terms this was a open-label study.

Everyone knew when Octreotide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

The researchers therefore evaluated the response to and the induction of resectability of primarily or locally recurrent unresectable thymomas and thymic carcinomas by octreotide Long-Acting Release (LAR) plus prednisone therapy in patients with positive octreotide scans.

Topics PubMed links to this paper include Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Octreotide, Prednisone, Thymoma and Thymus Neoplasms.

What This Means in Plain Language

The paper is an open-label study of Octreotide in 17 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2016 (PloS one), a journal based in United States.

More context: the Octreotide compound page.